Skip to main content
Equibles
TRDA logo

TRDA · Entrada Therapeutics, Inc. · Metrics

Track TRDA — free

Use TRDA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TRDA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.17 -0.27 (-4.96%) At close · Nov 12 Play latest call Q1 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Nov 5, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As a result of our recurring losses from operations and recurring negative cash flows from operations, there is substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed Nov 5, 2026
Market Cap
$202.41M
Shares
39.15M
Volume · Nov 12 808.67K Avg daily vol (3M) 365.68K

TRDA metrics

81 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$5.17
Market cap
$202.41M

Price action

23 metrics
Price change (1W)
+7.5%
Price change (30D)
+11.9%
Price change (3M)
-29.1%
Price change (6M)
-25.7%
Price change (YTD)
-47.1%
Price change (1Y)
-29.4%
Trailing year
Price change (5Y)
-83.3%
52-week high
$16.03
52-week low
$4.37
Change from 52-week high
-66.1%
Change from 52-week low
+24.5%
Annualized volatility
91.2%
Annualized volatility (3M)
90.7%
Implied volatility (30D)
169.1%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.4
RSI (14D)
54.1
Price vs SMA 50
-4.2%
Price vs SMA 200
-36.2%
Avg volume (3M)
357,295
Relative volume
2.1
Average dollar volume
$2.08M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
39.15M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
25.3×
reciprocal yield 3.9%
EV / EBITDA
—
EV / EBIT
—
P / sales
53.6×
reciprocal yield 1.9%
P / book
1.1
reciprocal yield 93.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-75.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
10.0×
reciprocal yield 10.0%
EV / revenue historical average (5Y)
10.0×
reciprocal yield 10.0%
EV / EBIT historical average (3Y)
20.5×
reciprocal yield 4.9%
EV / EBIT historical average (5Y)
20.5×
reciprocal yield 4.9%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-05-07

Profitability

9 metrics
Gross margin
—
Operating margin
-4,303.8%
Trailing 12 months
Net margin
-4,058.0%
Gross profit (TTM)
—
Operating profit (TTM)
−$171.16M
Net income (TTM)
−$161.39M
Trailing 12 months
Diluted EPS (TTM)
$-3.85
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.09
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-4.07
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-3.84
Operating cash flow per diluted share (TTM)
$-3.25
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$3.21
Stock compensation per diluted share (TTM)
$0.45
Book value per share
$8.00

Growth

11 metrics
Revenue growth YoY
-43.9%
Year over year
Net income growth YoY
-319.0%
Revenue (TTM)
$3.98M
Trailing 12 months
EPS growth YoY
-306.5%
Shares change YoY
+2.2%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-81.4%
Return on assets
-60.5%
Debt / equity
0.0
Current ratio
7.8
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
7.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$112.24M
Latest balance sheet
Cash & equivalents
$112.24M
Total assets
$266.88M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$136.32M
Capital expenditures (TTM)
$9,000
R&D (TTM)
$134.75M
SG&A (TTM)
—
Stock compensation (TTM)
$19.03M
R&D / revenue
3,388.2%
Stock compensation / revenue
478.5%

Ownership (13F)

9 metrics
13F filers
128
13F filer change QoQ
+9
Institutional ownership
74.3%
Conviction holders (share of 13F filers)
2.3%
Crowding (high-turnover and private-fund holders)
39.6%
Private-fund adviser ownership
38.6%
Active holders' share change QoQ
+17.0%
Holder tenure
12.4
Price vs estimated holder cost
-54.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
10.2%

Short interest

3 metrics
Short interest
7.2%
Latest settlement · 6.9 days to cover
Days to cover
6.9d
Short-squeeze score
59 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1689375 CUSIP 29384C108 13F (30d) 70 filings 57 filers Visit website Investor relations